American Society of Hirudotherapy

Discovery of a Thrombin-Targeting Anticoagulant Peptide From Whitmania pigra via a 'Computation-Guided Experimentation' Strategy

Drug discovery published in J Pept Sci (2025)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportDrug DevelopmentSalivary PharmacologyGenomics & ProteomicsHua YT et al. · Journal of peptide science : an official publication of the European Peptide Society, 2025

Abstract

Targeting thrombin to screen safe thrombin inhibitors from natural plants and animals is a critical direction in anticoagulant drug development. This study aimed to screen thrombin inhibitors from the nonbloodsucking leech Whitmania pigra (WP) and elucidate the mechanism of anticoagulation through a "computation-guided experimentation" strategy. A peptide library was constructed from WP hydrolysates, and virtual screening was performed using molecular docking and dynamics simulations. A novel thrombin-targeting anticoagulant peptide PEPWP (LRELEDALEQER) was screened out from the peptide library and validated through in vitro/in vivo experiments. PEPWP significantly prolonged thrombin time (TT) and prothrombin time (PT) in a dose-dependent manner in vitro, indicating its role in the common and extrinsic coagulation pathways. Surface plasmon resonance (SPR) analysis then confirmed strong thrombin binding (Kd = 7.242 × 10-6 mol/L). Furthermore, PEPWP prolonged TT while reducing blood viscosity in acute blood stasis rats. Finally, structural analysis revealed that PEPWP bound to Exosite II of thrombin. Arg233 and Arg101 were the key residues for the binding. In conclusion, PEPWP exhibited good anticoagulant activity and significant application potential.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsThrombinAnticoagulantsRatsMolecular Docking SimulationPeptidesLeechesHumansPeptide LibraryMaleBlood CoagulationThrombin Time

Summary

A computation-guided screen of Whitmania pigra hydrolysates identified PEPWP (LRELEDALEQER), a thrombin-targeting peptide that dose-dependently prolonged thrombin and prothrombin times in vitro, bound thrombin Exosite II, and prolonged thrombin time in rats.

Why This Matters for Hirudotherapy

This study employed a 'computation-guided experimentation' strategy to identify PEPWP, a novel thrombin-targeting anticoagulant peptide from the nonbloodsucking leech Whitmania pigra. The peptide was shown to prolong coagulation times in vitro and reduce blood viscosity in rat models of acute blood stasis. The paper highlights the potential for discovering new antithrombotic agents within leech-derived compounds. This is a preclinical study utilizing computational models, in vitro assays, and rat subjects, with no human or live leech therapy data.

Citation

Reference (Vancouver style)

Hua YT, Dong RJ, Li Y, Su ZY, Xin QC, Shen M, et al. Discovery of a Thrombin-Targeting Anticoagulant Peptide From Whitmania pigra via a 'Computation-Guided Experimentation' Strategy. J Pept Sci. 2025;31(10):e70056. doi:10.1002/psc.70056. PMID: 40922112

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 26, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.